Skip to main content

Table 1 Baseline characteristics

From: Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

Parameters

TAC + MTX

(n = 34)

TNFi + MTX

(n = 80)

P-value

Age, years

51.3 ± 9.7

50.5 ± 10.9

0.8598

Females, n (%)

31 (91.2)

64 (80.0)

0.1430

Body mass index, kg/m2

23.0 ± 2.5

23.0 ± 2.8

0.9284

Disease duration, months

95.0 ± 50.8

90.3 ± 70.0

0.2797

RF positivity, n (%)

27 (79.4)

65 (81.2)

0.8219

ACPA positivity, n (%)

32 (94.1)

64 (80)

0.0594

Tender joint count (0–68)

0.2 ± 0.7

0.2 ± 0.4

0.2760

Swollen joint count (0–66)

0.1 ± 0.5

0.1 ± 0.3

0.8964

PhGA (VAS, mm)

9.3 ± 10.6

10.0 ± 8.3

0.7022

PGA (VAS, mm)

15.4 ± 14.3

17.3 ± 17.9

0.5827

ESR, mm/h

21.3 ± 14.9

20.6 ± 13.5

0.8092

CRP, mg/dL

0.31 ± 0.48

0.23 ± 0.30

0.2833

DAS28-CRP

1.28 ± 0.48

1.25 ± 0.29

0.6820

HAQ-DI

0.28 ± 0.32

0.43 ± 0.50

0.1097

Larsen score

12.5 ± 19.1

12.1 ± 20.5

0.9190

MTX dose, mg/week

10.0 ± 2.3

10.8 ± 2.9

0.1398

Glucocorticoids, n (%)

16 (47.1)

43 (53.8)

0.5173

  1. Continuous variables are presented as means ± standard deviations unless otherwise indicated. ACPA, anti-citrullinated peptide antibody; CRP, C-reactive protein; DAS28-CRP, Disease Activity Score for 28 joints based on CRP; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; PhGA, Physician’s Global Assessment of Disease Activity; PGA, Patient’s Global Assessment of Disease Activity; RF, rheumatoid factor; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale; TAC, tacrolimus